[1] ZHENG Q,COX I A,CAMPBELL J A,et al.Mortality and survival in idiopathic pulmonary fibrosis:A systematic review and meta-analysis[J].ERJ Open Res,2022,8(1):00591-2021. [2] GHAZIPURA M,MAMMEN M J,BISSELL B D,et al.Pirfenidone in Progressive Pulmonary Fibrosis:A systematic review and Meta-Analysis[J].Ann Am Thorac Soc,2022,19(6):1030-1039. [3] FINNERTY J P,PONNUSWAMY A,DUTTA P,et al.Efficacy of antifibrotic drugs,nintedanib and pirfenidone,in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis(IPF)and non-IPF:a systematic review and meta-analysis[J].BMC Pulm Med,2021,21(1):411. [4] PITRE T,MAH J,HELMECZI W,et al.Medical treatments for idiopathic pulmonary fibrosis:a systematic review and network meta-analysis[J].Thorax,2022,77(12):1243-1250. [5] 柯月娇. 近5年医院制剂复方甘草口服溶液质量回顾分析[J].安徽医药,2022,26(1):205-208. [6] 刘春明,张洪,李一鸣.Fleischner学会关于特发性肺纤维化诊断标准的白皮书解读[J].国际医学放射学杂志,2018,41(6):653-657. [7] 于娜,周家为,李霞,等.成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J].中国现代医学杂志,2023,33(14):1-8. [8] PETNAK T,LERTJITBANJONG P,THONGPRAYOON C,et al.Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis:A systematic review and Meta-Analysis[J].Chest,2021,160(5):1751-1763. [9] KARUGA F F,KACZMARSKI P,SZMYD B,et al.The association between idiopathic pulmonary fibrosis and obstructive sleep apnea:A systematic review and Meta-Analysis[J].J Clin Med,2022,11(17):5008. [10] 赵稳,王延生,周霞,等.肺纤维化急性加重患者短期内死亡危险因素分析[J].广州医药,2020,51(5):1-4. [11] PAUCHET A,CHAUSSAVOINE A,PAIRON J C,et al.Idiopathic pulmonary fibrosis:What do we know about the role of occupational and environmental determinants?A systematic literature review and Meta-Analysis[J].J Toxicol Environ Health B Crit Rev,2022,25(7):372-392. [12] 李彬,别志欣,李元明,等.CT引导下经皮穿刺活检同步微波消融治疗特发性肺间质纤维化合并Ⅰ期非小细胞肺癌[J].中国介入影像与治疗学,2023,20(6):325-329. [13] 杨天舒,张晓梅,李睿,等.姜良铎从状态论治特发性肺间质纤维化慢性发热[J].中华中医药杂志,2023,38(6):2648-2651. [14] 魏祎,齐鸣,黄丽羽,等.岩白菜素治疗特发性肺间质纤维化的研究[J].医学研究生学报,2022,35(5):493-498. [15] 顾一丹,任允琰,章朱峰,等.基于网络药理学与分子对接探索人参-五味子配伍治疗特发性肺间质纤维化的分子机制[J].山东科学,2022,35(1):28-36. [16] 赵海鹏,齐衍超,祁立新,等.市售复方甘草片的质量评价[J].中国现代应用药学,2022,39(13):1737-1743. [17] 肖琼华,姚婷,吴琼,等.基于倾向性评分匹配法的祛痹化纤方治疗特发性肺间质纤维化疗效评价[J].辽宁中医杂志,2023,50(3):145-148. [18] 魏秀丽,张传津,刘道中,等.UPLC-PDA联合UPLC-MS/MS法确证一批标称杨树花口服液中非法添加物甘草酸[J].中国兽药杂志,2023,57(10):47-53. [19] 焦欢,李龙.炎性指标与特发性肺间质纤维化并发呼吸衰竭的相关性分析[J].解放军医学杂志,2023,48(3):298-303. [20] 魏祎,刘超,齐鸣,等.岩白菜素通过调控NF-κB/NLRP3通路和代谢对特发性肺间质纤维化小鼠的影响[J].中成药,2023,45(1):62-69. [21] 陈熔,王旭,舒静,等.特发性肺间质纤维化急性加重患者呼吸道微生态成分与不良预后的关系[J].疑难病杂志,2022,21(11):1141-1146. [23] 康冬梅,高勇,马继芳,等.特发性肺间质纤维化并发肺气肿的风险模型构建与评价[J].疑难病杂志,2022,21(12):1236-1241. [24] 刘薇,张玲,鲍洁,等.特发性肺间质纤维化患者预后不良的影响因素及预测价值[J].川北医学院学报,2022,37(4):426-429. [25] 冯碧阳,陈黎明.复方甘草片引起低血钾并发电交感风暴致病人反复晕厥1例报道[J].中西医结合心脑血管病杂志,2023,21(21):4043-4046. |